Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012; 18:6049-57.
Sep 12, 2012
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Sep 12, 2012
Clin Cancer Res 2012; 18:6049-57
Cathomas Richard, Gillessen Sommer Silke, von Moos Roger, Schiess Ralph, Pless Miklos, Berthold Dominik R, Siciliano Daniele, Winterhalder Ralph, Droege Cornelia, Cotting Denise, Brauchli Peter, Betticher Daniel C, Jaggi Rolf, Bubendorf Lukas, Klingbiel Dirk, Rothermundt Christian, Swiss Group for Clinical Cancer Research SAKK
more